XLO
XLO
NASDAQ · Biotechnology

Xilio Therapeutics Inc

$8.32
-0.36 (-4.15%)
As of Mar 29, 10:51 PM ET ·
Financial Highlights (FY 2026)
Revenue
8.43M
Net Income
-77,429,863
Gross Margin
Profit Margin
-918.1%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 31.0% 31.0% 31.0%
Operating Margin -954.9% -12.7% -12.5% -13.4%
Profit Margin -918.1% -10.6% -13.0% -12.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 8.43M 12.59M 12.91M 9.78M
Gross Profit 3.90M 4.00M 3.03M
Operating Income -80,540,884 -1,593,118 -1,614,371 -1,306,842
Net Income -77,429,863 -1,338,243 -1,683,285 -1,199,258
Gross Margin 31.0% 31.0% 31.0%
Operating Margin -954.9% -12.7% -12.5% -13.4%
Profit Margin -918.1% -10.6% -13.0% -12.3%
Rev Growth -1.9% -7.4% -8.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 16.15M 16.94M 14.90M
Total Equity 15.37M 18.19M 17.29M
D/E Ratio 1.05 0.93 0.86
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -75,111,098 -1,969,871 -1,762,148 -1,377,431
Free Cash Flow -1,414,748 -1,276,245 -1,101,740